FDA OKs name for plasma therapy. (Media & Technology).The Food and Drug Administration has approved a name change for Glendale-based biotech ZLB ZLB Zero Length Body ZLB Zero Length Bit Bioplasma Inc.'s intravenous blood product, Intravenous immunoglobulin Pete DeHart, ZLB president, said the company agreed to change the name of IVIG IVIG Intravenous immunoglobulin, see there to Carimmune Immune Globulin Immune globulin Serum containing antibodies against a specific infection. Mentioned in: Maternal to Fetal Infections Intravenous (Human) in order to better reflect the company's focus on caring for patients and medical professionals. "We try to demonstrate daily that we care about the health care community," DeHart said. "We do everything we can to assist our customers, from ensuring product availability for patients to assisting doctors with reimbursement issues." Carimmune, pronounced "care immune," is a freeze-dried product made from human blood plasma blood plasma n. The yellow or gray-yellow, protein-containing fluid portion of blood in which the blood cells and platelets are normally suspended. taken from U.S. donors. The plasma is particularly enriched with antibodies that are therapeutic for patients suffering from immune deficiency disorders and diseases. The company said it plans to begin distributing Carimmune immediately to hospitals, clinics and physicians. By law, the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. must approve any changes in names or packaging of any previously approved products. ZLB is a U.S. subsidiary of CSL Limited of Australia. Business Journal reporter Carlos Martinez may by reached at (818) 676-1750 ext. 17 or by e-mail at cmartinez@sfvbj.com |
|
||||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion